Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cambrex Corporation    CBM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/20/2017 07/21/2017 07/24/2017 07/25/2017 07/26/2017 Date
58.85(c) 58.9(c) 59.45(c) 59.1(c) 59 Last
172 143 187 570 176 300 233 430 42 384 Volume
+0.51% +0.08% +0.93% -0.59% -0.17% Change
More quotes
Financials ($)
Sales 2017 537 M
EBIT 2017 139 M
Net income 2017 94,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 576 M
EBIT 2018 152 M
Net income 2018 103 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 20,52
P/E ratio 2018 19,33
Capi. / Sales2017 3,59x
Capi. / Sales2018 3,34x
Capitalization 1 925 M
More Financials
Company
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics.It supplies to innovator and generic pharmaceutical companies.Its products include generic and branded APIs, controlled... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Surperformance© ratings of Cambrex Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CAMBREX CORPORATION
10:42a CAMBREX CORPORATION : Shares Sold by First National Bank of Omaha
07/20 CAMBREX : Wombat Capital - Winner of the 7th Annual ACG New York Champion's Awar..
06/01 CAMBREX : invests in Sweden facility
05/31 CAMBREX : to Present at the Jefferies 2017 Global Healthcare Conference
05/30 CAMBREX : Invests in New Capacity and Continuous Flow Technology at its Karlskog..
05/19 CAMBREX : invests $2.4m at former PharmaCore site
05/18 CAMBREX : invests $2.4m at former PharmaCore site
05/18 CAMBREX : Invests $2.4M in API Capacity at NC Facility
05/17 CAMBREX : Invests to increase pilot scale api capacity at its high point, nc fac..
05/16 CAMBREX : Invests to Increase Pilot Scale API Capacity at its High Point, NC Fac..
More news
Sector news : Pharmaceuticals - NEC
07/25DJGlaxoSmithKline Names Former Wal-Mart Executive as Chief Digital and Technolo..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/25DJABBVIE : Jury Backs AbbVie Payment -- WSJ
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24DJABBVIE : Ordered to Pay $150 Million in AndroGel Lawsuit
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/19Cambrex Corporation $CBM Stake Decreased by AQR Capital Management LLC  
07/16Cambrex Corporation $CBM Stake Reduced by Teachers Advisors LLC  
07/06Steven M. Klosk Sells 12,000 Shares of Cambrex Corporation $CBM Stock  
07/05Cambrex Corporation $CBM Lowered to “Hold” at Zacks Investment Research  
07/05Cambrex Corporation downgraded by Zacks Investment Research to hold.  
More tweets
Qtime:14
News from SeekingAlpha
06/29 ACADIA PHARMACEUTICALS : Biotech Stocks In Renewed Price Interest
06/08 Cambrex (CBM) Presents At Jefferies 2017 Global Healthcare Conference - Slide..
05/23 Cambrex Corporation (CBM) Presents At UBS Global Healthcare Conference 2017 -..
05/06 Cambrex's (CBM) CEO Steve Klosk on Q1 2017 Results - Earnings Call Transcript
05/04 Cambrex beats by $0.20, beats on revenue
Chart CAMBREX CORPORATION
Duration : Period :
Cambrex Corporation Technical Analysis Chart | CBM | US1320111073 | 4-Traders
Technical analysis trends CAMBREX CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 65,5 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Steven M. Klosk President, Chief Executive Officer & Director
Shlomo Yanai Non-Executive Chairman
Shawn P. Cavanagh Chief Operating Officer & Executive Vice President
Tom Vadaketh Chief Financial Officer & Vice President
Peter G. Tombros Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CAMBREX CORPORATION9.55%1 925
JOHNSON & JOHNSON14.47%358 307
ROCHE HOLDING LTD.4.30%221 333
NOVARTIS7.35%220 169
PFIZER1.91%198 425
MERCK AND COMPANY5.93%171 139